Sector News

India’s Sun Pharma open to large acquisitions post Ranbaxy deal

March 25, 2015
Life sciences
(Reuters) – Sun Pharmaceutical Industries Ltd, India’s largest drugmaker by sales, said on Wednesday its $3.2 billion acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.
 
The company will look to invest more than $300 million in research and development and is not considering any job cuts post the close of the deal, Managing Director Dilip Shanghvi told reporters in Mumbai.
 
Shanghvi, who founded Sun Pharma and is one of the country’s richest men, added that the company’s “most important focus” would be to win confidence of regulators.
 
Sun Pharma’s third-quarter profit was hit by costs incurred to address observations raised by the U.S. Food and Drug Administration after an inspection of the company’s manufacturing plant in western India.
 
“Every investment I have made outside of Sun is financial, I have no interest in running those businesses,” said Shanghvi, who invested $290 million for a 23 percent stake in wind turbine maker Suzlon Energy Ltd last month.
 
The company’s shares were up 1 percent in afternoon trading on Wednesday, while the benchmark index was down 0.16 percent. (Reporting by Zeba Siddiqui in Mumbai; Writing by Aman Shah; Editing by Anand Basu)
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach